{
    "clinical_study": {
        "@rank": "48493", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1 SAD", 
                "arm_group_type": "Experimental", 
                "description": "NGM282 Dose 1 vs Placebo"
            }, 
            {
                "arm_group_label": "Cohort 2 SAD", 
                "arm_group_type": "Experimental", 
                "description": "NGM282 Dose 2 vs Placebo"
            }, 
            {
                "arm_group_label": "Cohort 3 SAD", 
                "arm_group_type": "Experimental", 
                "description": "NGM282 Dose 3 vs Placebo"
            }, 
            {
                "arm_group_label": "Cohort 4 SAD", 
                "arm_group_type": "Experimental", 
                "description": "NGM282 Dose 4 vs Placebo"
            }, 
            {
                "arm_group_label": "Cohort 5 SAD", 
                "arm_group_type": "Experimental", 
                "description": "NGM282 Dose 5 vs Placebo"
            }, 
            {
                "arm_group_label": "Cohort 6 SAD", 
                "arm_group_type": "Experimental", 
                "description": "NGM282 Dose 6 vs Placebo"
            }, 
            {
                "arm_group_label": "Cohort 7 MAD", 
                "arm_group_type": "Experimental", 
                "description": "NGM282 Dose 1 vs Placebo"
            }, 
            {
                "arm_group_label": "Cohort 8 MAD", 
                "arm_group_type": "Experimental", 
                "description": "NGM282 Dose 2 vs Placebo"
            }, 
            {
                "arm_group_label": "Cohort 9 MAD", 
                "arm_group_type": "Experimental", 
                "description": "NGM282 Dose 3 vs Placebo"
            }, 
            {
                "arm_group_label": "Cohort 10 MAD", 
                "arm_group_type": "Experimental", 
                "description": "NGM282 Dose 4 vs Placebo"
            }, 
            {
                "arm_group_label": "Cohort 11 MAD", 
                "arm_group_type": "Experimental", 
                "description": "NGM282 Dose 5 vs Placebo"
            }, 
            {
                "arm_group_label": "Cohort 12 MAD", 
                "arm_group_type": "Experimental", 
                "description": "NGM282 Dose 6 vs Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety and tolerability of NGM282, both single\n      dose and multiple doses, in normal healthy adult participants."
        }, 
        "brief_title": "Phase 1 SAD and MAD Study of NGM282 in Healthy Adult Participants", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": "Diabetes Mellitus"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males or females, between 18 and 65 years of age, inclusive\n\n          -  BMI range is 20-35 kg/m2, inclusive for the SAD Module, and 25-35 kg/m2, inclusive\n             for the MAD Module at Screening;\n\n          -  In good health, determined by no clinically significant findings from medical\n             history, physical exam, 12 lead ECG, clinical laboratory findings, and vital signs at\n             Screening and Day -1\n\n        Exclusion Criteria:\n\n          -  Significant history or clinical manifestation of any significant metabolic, allergic,\n             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, GI,\n             neurological, or psychiatric disorder (as determined by the PI)\n\n          -  History of significant hypersensitivity, intolerance, or allergy to any drug\n             compound, food, or other substance"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "119", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01776528", 
            "org_study_id": "12-0101"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 1 SAD", 
                    "Cohort 2 SAD", 
                    "Cohort 3 SAD", 
                    "Cohort 4 SAD", 
                    "Cohort 5 SAD", 
                    "Cohort 6 SAD", 
                    "Cohort 7 MAD", 
                    "Cohort 8 MAD", 
                    "Cohort 9 MAD", 
                    "Cohort 10 MAD", 
                    "Cohort 11 MAD", 
                    "Cohort 12 MAD"
                ], 
                "intervention_name": "NGM282", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Cohort 1 SAD", 
                    "Cohort 2 SAD", 
                    "Cohort 3 SAD", 
                    "Cohort 4 SAD", 
                    "Cohort 5 SAD", 
                    "Cohort 6 SAD", 
                    "Cohort 7 MAD", 
                    "Cohort 8 MAD", 
                    "Cohort 9 MAD", 
                    "Cohort 10 MAD", 
                    "Cohort 11 MAD", 
                    "Cohort 12 MAD"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 30, 2013", 
        "link": {
            "url": "http://ngmbio.com/"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Perth", 
                    "country": "Australia", 
                    "state": "Western Australia", 
                    "zip": "6009"
                }, 
                "name": "NGM Clinical Study Site"
            }
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "12", 
        "official_title": "A Phase 1 Randomized, Double Blind, Placebo Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NGM282 in Healthy Adult Participants", 
        "overall_official": {
            "affiliation": "NGM Biopharmaceuticals, Inc", 
            "last_name": "Alex M DePaoli, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To evaluate the safety and tolerability of single ascending doses and multiple ascending doses of NGM282 in healthy adult participants.", 
            "measure": "Safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "7 days and 14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01776528"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate the pharmacokinetics of single ascending doses and multiple ascending doses of NGM282 in healthy adult participants.", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "7 days and 14 days"
            }, 
            {
                "description": "To evaluate the pharmacodynamics of single ascending doses and multiple ascending doses of NGM282 in healthy adult participants.", 
                "measure": "Pharmacodynamics", 
                "safety_issue": "No", 
                "time_frame": "7 days and 14 days"
            }
        ], 
        "source": "NGM Biopharmaceuticals, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "NGM Biopharmaceuticals, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}